Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

If you are looking at ABIVAX Société Anonyme and wondering whether the huge run up has left any value on the table, you are not alone. This stock has gone from niche biotech to serious talking point ...

CRISPR Therapeutics is a leading biotech company, currently developing gene-editing techniques to cure hereditary diseases with promising projects underway. The company's Q1 2023 revenue was 100M USD ...

Legend Biotech (LEGN) has been sliding lately, with the stock down about 24% over the past month and nearly 29% in the past 3 months, despite solid double digit revenue growth. See our latest analysis ...

If you are wondering whether Genmab is still a smart buy after its big run in biotech, you are not alone. That is exactly what this breakdown is going to tackle. The stock is up 31.6% year to date and ...